



## Brief Report

### High Level Delegation to Shanghai

&

### China International Import Expo(CIIE)

4-10<sup>th</sup> November 2018

National Exhibition and Convention Centre(NECC),Shanghai ,China

### Visit of High level Delegation from India to CIIE during 4<sup>th</sup> - 6<sup>th</sup> November 2018

The Delegation led by Mr. Anup Wadhawan, Secretary, Department of Commerce visited Shanghai during 4<sup>th</sup> -6<sup>th</sup> November 2018 accompanied by the following officials from the Department and Industry:

- Mr. Shyamal Misra, Joint Secretary, Department of Commerce
- Mr. Suresh Kumar Vasshith, Joint Secretary, Department of Food & Public Distribution
- Ms. Monideepa Mukherjee, ADG(Media), Department of Commerce
- Mr. Prashant Lokhande, Counsellor Economic, Embassy of India, Beijing
- Mr. Uday Bhaskar, Director General, Pharmexcil (dealing with export of pharma products)
- Mr. Ajay Sahai, Director General, FIEO (coordinating the country pavilion)
- Mr. Paban Borthakur, Chairman, APEDA (dealing with export of agriculture products)
- Mr. Sanjeev Chadha, Managing Director, NAFED (coordinating export of rapeseed/soyameal)

The delegation was coordinated by the Department of Commerce and the Embassy of China in New Delhi and Embassy of India at Beijing.

Commerce Secretary participated in the “Welcome Banquet” organised by the Embassy of China on 4<sup>th</sup> November 2018 and meetings organised with MOFCOM, COFCO, Vice Minister, China on the export of Sugar and market access issues on the sidelines of the event.

Commerce Secretary on 5<sup>th</sup> November 2018 convened a meeting with the Delegation representing Department Officials and the Council officials seeking inputs and issues that can be taken up with China side:

Mr. Shyamal Misra, Joint Secretary, Department of Commerce representing Pharma sector presented the following issues pertaining to pharmaceuticals sector:

- 1) Delays in product registration approvals by NMPA(formerly CFDA)
- 2) Waiver for local BE study based on overseas BE done as part of US/EU/Japan filing.
- 3) Differential treatment in Government Procurement of Pharmaceuticals (by various provinces).
- 4) Requested for organising training programme on recent regulatory developments and dossier filing with NMPA-pursing with CCCMPHIE and Pharmexcil is willing to host the training programme for the benefit of member companies.
- 5) Duplicate Copy of IDL to be provided to the exporter.
- 6) Batch testing and analysis to be done on random basis.
- 7) Interface between CFDA and NMPA (formerly CFDA) to be established for better understanding and regular exchange of information.

Mr. Uday Bhaskar, Director General Pharmexcil briefed the Secretary that Pharmexcil organised B2B meetings during 20-22<sup>nd</sup> August 2018 and also signed a MoU with CCCMPHIE for greater market access in the area of Pharmaceuticals. Pharmexcil is pursuing with CCCMPHIE for organising the training programme with NMPA and has expressed its willingness to host the training programme in India and China.

### PHARMEXCIL participation at China International Import Fair: 5-10<sup>th</sup> Nov.2018

Pharmexcil participated in the “**India Pavilion**” organised by Federation of Indian Exporters Organisation (FIEO) at China International Import Expo held from 5-10<sup>th</sup> Nov.2018 at National Exhibition and Convention Centre (NECC) Shanghai, China. The following sectors actively participated and showcased the strengths of India at CIIE:

- Pharmaceuticals
- IT & ITES
- Tourism & Services
- Food & Agriculture
- Marine Food processing

On 5<sup>th</sup> Nov.2018 Commerce Secretary, Mr. Anup Wadhawan inaugurated the “**India Pavilion**” (organised by FIEO) and visited Pharmexcil Stand in China International Import Expo held at Shanghai.



A total of 172 countries, regions and international organizations (about 3600) from five continents participated and showcased their development achievements and international image at the first China International Import Expo (CIIE).

The CIIE is "a major policy for China to push for a new round of high-level opening-up and a major measure for China to take the initiative to open its market to the world," Xi said when delivering a keynote speech at the opening ceremony.

Pharmexcil stand was visited by importers and traders dealing with bulk drugs, pharmaceuticals, mostly relating to anti-cancer drugs. Many traders are looking for anti-cancer drugs from India and interested to know how to import from India.

The procedure requires registration of these cancer drugs with NMPA (formerly CFDA), which is not happening at the moment, leaving the availability and accessibility of these medicines in question to the general Chinese population.

Pharmexcil has been approached by Hainan province informing that they are interested to work with the Council on the investment opportunities in Hainan province and Indian pharmaceutical industries are invited to invest in the Pharma park of Hainan province. The province of Hainan is also interested to import certain pharmaceuticals provided it is registered with NMPA and requested that the list of approved drugs may be shared with the Hainan for procurement from India side.



Mr.Bhaskar, Director General and Mr.Murali Krishna, Joint Director Pharmexcil met Ms.Guo Xiaodon, Incharge Information Desk and Deputy Director of China Chamber of Commerce of Import & Export of Medicines and Health Products (CCCMHPIE) on 6<sup>th</sup> November for finalising the programmes for the calendar year 2019.It is decided to continue the B2B and Pharma Conference meeting during September 2019 and two regulatory training programmes during the year 2019.A Indo-China symposium is also proposed, which will be organised by CDSCO India and NMPA ,supported by Pharmexcil, to encourage dialogue and regular exchange of information between CDSCO and NMAP(formerly CFDA)

Mr.Uday Bhaskar was invited by M/s.China Chinopharma Ltd to visit their Corporate Office and warehouse facility on 7<sup>th</sup> November 2018. Mr.Bhaskar visited the Office and warehouse facility of by M/s.China Chinopharma Ltd and discussed with Mr.Mersummer, Managing Director on the forthcoming regulatory training programme proposed in Hyderabad and suggested to hold the training programme at the earliest possible without waiting for January 2019,which was accepted and now scheduled for 17<sup>th</sup> Dec.2018 at Hyderabad.

During the exhibition of 5 days, Pharmexcil has received about 20 trade enquiries in total varying from product specific queries (cancer drugs and APIs) to investment opportunities and custom manufacturing interests from China.

Mr.Murali Krishna, Joint Director attended the exhibition from 5-10<sup>th</sup> Nov.2018 from Pharmexcil.